Jessika Valero Gonzalez: Antibody Engineering and Early Cancer Detection | Stories in Life Sciences

Many promising cancer proteins are nearly impossible to detect. Not because of biology, but because of engineering. Christopher Wilson sits down with Jessika Valero Gonzalez, Chief Research Officer at BioClonal, to explore how advanced antibody engineering is unlocking targets that traditional methods and animal models miss.Jessika's path runs from chemistry and protein science into biotech leadership, driven by a clear mission to translate science into patient impact. At BioClonal, she is helping build a platform focused on monoclonal antibodies for challenging cancer targets, using inverse engineering and super immunogens to overcome the limitations of conventional approaches.In this episode of Stories in Life Sciences, we cover:Why many cancer detection failures are engineering problems, not biology problemsHow inverse engineering and super immunogens unlock targets animal models missBioClonal's platform approach to monoclonal antibody development for challenging targetsCommercialization strategy: platform partnerships versus internal pipeline developmentWhy early market feedback is critical in long biotech development cyclesWhat it takes to move deep biotech innovation from lab to marketJessika's journey from chemistry and protein science to biotech leadershipWho this is for: researchers, founders, and investors in oncology, antibody engineering, biotech diagnostics, and life sciences commercialization who want to understand where cancer detection technology is headed.Guest: Jessika Valero GonzalezChief Research Officer, BioClonal https://bioclonal.eshttps://www.linkedin.com/company/bioclonalhttps://www.linkedin.com/in/jessika-valeroHost:Christopher Wilson, Founder, MedAxis AIwww.medaxisai.orghttps://www.linkedin.com/in/christopher-wilson-medaxisai https://www.linkedin.com/company/medaxisaiFollow Stories in Life Sciences on Spotify, Apple Podcasts, and YouTube for new episodes.